OncLive TV

Karine Tawagi, MD, discusses the use of targeted therapies in the management of metastatic prostate cancer.

Vered Stearns, MD, discusses the efficacy of avelumab as adjuvant therapy in patients with early triple-negative breast cancer.

Peter Martin, MD, discusses the role of BTK inhibitors in the treatment of mantle cell lymphoma.

Justin M. Watts, MD, discusses the potential advantages of the oral small molecule BET inhibitor INCB057643 in advanced myelofibrosis.

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates under investigation in ovarian cancer.

Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.

Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

Timothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.

Jordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma.

James J. Harding, MD, discusses the significance of the FDA approval of zanidatamab for pretreated, unresectable or metastatic HER2+ biliary tract cancer.

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

Adam E. Singer, MD, PhD, discusses the safety profiles of immuno-oncology/TKI regimens in first-line renal cell carcinoma.

Diane Reidy-Lagunes, MD, discusses key trials that have expanded the treatment paradigm for patients with neuroendocrine tumors.

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Kevin Kalinsky, MD, MS, discusses the phase 3 DESTINY-Breast06 trial evaluating trastuzumab deruxtecan in HER2-expressing breast cancer.

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

Howard S. Hochster, MD, FACP, discusses the role of cooperative group clinical trials in bridging the gap between academic and community cancer centers.

John H. Strickler, MD, discusses the role of biomarker testing in metastatic pancreatic cancer.

Brandon G. Smaglo, MD, FACP, discusses the ongoing research with RAS-targeted therapies for pancreatic cancer.

Cedric Pobel, MD, discusses the potential prognostic value of phenotypic and genomic characterization of de novo mCSPC from the phase 3 PEACE-1 trial.

Ruth O'Regan, MD, discusses considerations for sequencing strategies in advanced hormone receptor–positive breast cancer.

Michael R. Grunwald, MD, discusses the importance of monitoring risk factors associated with disease progression in patients with polycythemia vera.

Peter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.

John N. Allan, MD, discusses ongoing efforts to address areas of uncertainty regarding the optimal sequencing strategy in CLL.

Kathleen A. Dorritie, MD, discusses 5-year of follow-up data from the CAPTIVATE trial in chronic lymphocytic leukemia and/or small lymphocytic lymphoma.

Minoo Battiwalla, MD, MS, discusses how emerging therapies contribute to the management of aggressive variants of follicular lymphoma.

Kathleen N. Moore, MD, MS, discusses adverse effects associated with the use of antibody-drug conjugates for the treatment of gynecologic cancers.